Digoxin immune fab

Revision as of 11:08, 27 February 2014 by Abdurahman Khalil (talk | contribs)
Jump to navigation Jump to search
Digoxin Immune Fab
DIGIFAB® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Digoxin Immune Fab
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

For patient information about Digoxin immune fab, click here.

Synonyms / Brand Names: DIGIFAB ® injection

Overview

Digoxin Immune Fab (Ovine) is the generic name for an antidote for overdose of digitalis.[1] It is made from immunoglobin fragments from sheep who have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind and DigiFab, with the former manufactured by GlaxoSmithKline and the latter manufactured by Protherics, Inc.

Category

FDA Package Insert

DIGIFAB®

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

  1. DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL (2000). "Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity". J. Cardiovasc. Pharmacol. Ther. 5 (2): 77–85. PMID 11150387.

http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6832767f-db6b-4eea-b88b-bdfc905749e1